Context Therapeutics
Advancing T Cell Engagers for Solid Tumors
Advancing T Cell Engagers for Solid Tumors
Context Therapeutics is a biopharmaceutical company headquartered in Philadelphia, United States, that is dedicated to advancing medicines for solid tumors. The company's flagship product, CTIM-76, is a selective Claudin 6 (CLDN6) x CD3 bispecific antibody designed for CLDN6-positive tumors and is currently in the preclinical development phase. Since its founding in 2015, Context Therapeutics has garnered significant attention from investors, with their most recent $100.00M post-IPO equity investment on 02 May 2024 backed by a consortium of notable firms including Blackstone Group, Ally Bridge Group, Deep Track Capital, Driehaus Capital Management, Nextech Invest, Great Point Partners, Avidity Partners, and Blue Owl. For more information about Context Therapeutics, interested parties can visit their website at www.contexttherapeutics.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $100.00M | 8 |
|
02 May 2024 |
| Post-IPO Equity | $31.25M | - | 06 Dec 2021 | |
| Venture Round | Unknown | 1 |
|
15 Nov 2017 |
No recent news or press coverage available for Context Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
